{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:37:46Z","timestamp":1776163066654,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2015-0552"],"award-info":[{"award-number":["2015-0552"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Telethon Italy","award":["GGP14125"],"award-info":[{"award-number":["GGP14125"]}]},{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"publisher","award":["Z4623C6541"],"award-info":[{"award-number":["Z4623C6541"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.bbalip.2018.05.015","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T02:33:12Z","timestamp":1527561192000},"page":"991-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders"],"prefix":"10.1016","volume":"1863","author":[{"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Botta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Ossoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giovanna","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Magni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Pisciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Veglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2018.05.015_bb0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0025","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1194\/jlr.M049346","article-title":"Isolation and characterization of the circulating truncated form of PCSK9","volume":"55","author":"Han","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0030","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCRESAHA.113.302655","article-title":"Loss of plasma proprotein convertase subtilisin\/kexin 9 (PCSK9) after lipoprotein apheresis","volume":"113","author":"Tavori","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0035","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1210\/jc.2014-3066","article-title":"Removal of plasma mature and furin-cleaved proprotein convertase subtilisin\/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9","volume":"100","author":"Hori","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0040","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation","volume":"288","author":"Kosenko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0050","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacl.2017.03.001","article-title":"Discordant response of low density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin\/kexin type 9","volume":"11","author":"Edmiston","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence","volume":"173","author":"Ferri","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0070","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0075","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","article-title":"Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice","volume":"50","author":"Luo","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0085","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1161\/01.ATV.0000175751.30616.13","article-title":"The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families","volume":"25","author":"Calabresi","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2796.2008.02019.x","article-title":"Severe HDL deficiency due to novel defects in the ABCA1 transporter","volume":"265","author":"Pisciotta","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0095","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-9150(03)00020-0","article-title":"Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency","volume":"167","author":"Pisciotta","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacl.2015.09.001","article-title":"A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla)","volume":"9","author":"Pisciotta","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ymgme.2012.08.005","article-title":"Novel mutations of ABCA1 transporter in patients with tangier disease and familial HDL deficiency","volume":"107","author":"Fasano","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0110","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1194\/jlr.M200248-JLR200","article-title":"Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene","volume":"44","author":"Altilia","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.atherosclerosis.2003.11.009","article-title":"Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders","volume":"172","author":"Pisciotta","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0125","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biologicals.2013.09.007","article-title":"Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency","volume":"41","author":"Simonelli","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0130","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","article-title":"Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line","volume":"291","author":"Ruscica","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0135","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0140","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0145","first-page":"523","article-title":"The Quebec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth","volume":"19","author":"Paradis","year":"2003","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0150","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0155","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCRESAHA.113.300634","article-title":"Mendelian disorders of high-density lipoprotein metabolism","volume":"114","author":"Oldoni","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbalip.2014.07.015","article-title":"HDL and atherosclerosis: insights from inherited HDL disorders","volume":"1851","author":"Calabresi","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbalip.2018.05.015_bb0170","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1210\/jc.2016-4043","article-title":"Threshold effects of circulating angiopoietin-like 3 levels on plasma lipoproteins","volume":"102","author":"Fazio","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1194\/jlr.M600403-JLR200","article-title":"Role of LCAT in HDL remodeling: investigation of LCAT deficiency states","volume":"48","author":"Asztalos","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0180","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2014.02.538","article-title":"Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects","volume":"63","author":"Lambert","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005764","article-title":"Circulating levels of proprotein convertase subtilisin\/kexin type 9 and arterial stiffness in a large population sample: data from the Brisighella heart study","volume":"6","author":"Ruscica","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bbalip.2018.05.015_bb0190","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J. Lipid Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198118301185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198118301185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,15]],"date-time":"2019-12-15T20:04:46Z","timestamp":1576440286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198118301185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1388198118301185"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2018.05.015","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2018.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}